Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial ; volume:23 ; number:1 ; day:3 ; month:1 ; year:2023 ; pages:1-9 ; date:12.2023
BMC cancer ; 23, Heft 1 (3.1.2023), 1-9, 12.2023
- Urheber
-
Miura, Satoru
Koh, Yasuhiro
Azuma, Koichi
Yoshioka, Hiroshige
Koyama, Kenichi
Teraoka, Shunsuke
Ishii, Hidenobu
Kibata, Kayoko
Ozawa, Yuichi
Tokito, Takaaki
Oyanagi, Jun
Shimokawa, Toshio
Kurata, Takayasu
Yamamoto, Nobuyuki
Tanaka, Hiroshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-022-10467-w
- URN
-
urn:nbn:de:101:1-2023031909015536074400
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Miura, Satoru
- Koh, Yasuhiro
- Azuma, Koichi
- Yoshioka, Hiroshige
- Koyama, Kenichi
- Teraoka, Shunsuke
- Ishii, Hidenobu
- Kibata, Kayoko
- Ozawa, Yuichi
- Tokito, Takaaki
- Oyanagi, Jun
- Shimokawa, Toshio
- Kurata, Takayasu
- Yamamoto, Nobuyuki
- Tanaka, Hiroshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
Elevated exosome-derived miRNAs predict osimertinib resistance in non-small cell lung cancer
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis
Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation